Antidepressant Therapy in Treating Bipolar Type II Major Depression

University of Pennsylvania140 enrolled

Overview

This study will compare the safety and effectiveness of antidepressant therapy versus mood stabilizing therapy in treating people with bipolar type II major depression.

Bipolar type II (BP II) depression affects 2.5% of the U.S. adult population. People with BP II disorder do not experience the manic episodes that are characteristic of BP I disorder, but rather they experience more modest mood swings with a greater number of major depressive episodes (MDEs). These MDEs are associated with high rates of disease and death. The treatment of BP II depression remains a challenge for clinicians. Mood stabilizer (MS) monotherapy is the current recommended treatment for BD II MDE, but there is reason to believe that antidepressant drug (AD) monotherapy could also be an effective treatment. However, concerns over AD-induced manic switch episodes have limited the use of this treatment option. Preliminary studies using the ADs fluoxetine or venlafaxine have shown success in treating and lowering the manic switch rate of those with BP II MDE. This study will compare the safety and effectiveness of AD monotherapy versus MS monotherapy in treating people with BP II major depression. Participation in this double-blind study will last up to 9 months. After screening, which includes a medical and psychiatric history review, a physical exam, an electrocardiogram (EKG) test, clinical laboratory tests, a urine-based drug test, and a pregnancy test if applicable, participants will be randomly placed into one of two treatment groups. Participants in the AD monotherapy group will be treated with venlafaxine, and participants in the MS monotherapy group will be treated with lithium. During the first 12 weeks, there will be a total of nine study visits lasting between 45 and 60 minutes. In these visits, participants will receive their study drug and will undergo various assessments, including a review of medication history and side effects, vital sign measurements, and questionnaires about depression and daily functioning. Blood samples will be taken at most visits. Participants who respond well during the initial 12 weeks of therapy with either drug will have the option to continue treatment for 6 additional months. During this time, participants will continue their assigned treatment and will attend five monthly study visits that will repeat previous assessments and procedures. For information on a related study, please follow this link: http://clinicaltrials.gov/show/NCT00044616

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

140

Conditions

Bipolar Disorder Depression

Interventions

VenlafaxineDRUG

75 to 375 mg

Lithium CarbonateDRUG

300 to 2400 mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Meets DSM-IV criteria for Axis I bipolar II disorder * Meets DSM-IV criteria for Axis I major depressive episode * Score of 16 on 17-item HAM-D rating scale * Not taking monoamine oxidase inhibitors (MAOI) for more than 2 weeks prior to study entry * Willing to use an effective form of birth control throughout the study Exclusion Criteria: * History of mania * Current primary Axis I diagnosis other than bipolar II disorder * Alcohol or drug dependence within 3 months prior to study entry * Contraindication to treatment with venlafaxine or lithium * Unstable medical condition (e.g., thyroid disease, hypertension, or angina pectoris) * Pregnant or breastfeeding * Experiencing suicidal thoughts * Requires hospitalization * Requires concurrent neuroleptic or MS therapy * Requires concurrent AD therapy * Current psychotic features * Inadequate trial of therapy at the time of initial screening visit * History of intolerance to either venlafaxine or lithium * Unlikely to participate in a 36-week trial * Presence of apparent secondary gain

Locations (1)

Depression Research Unit - University of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Depressive Relapse

These subjects must be responders. Outcome measures were obtained at continuation weeks. Participant would be considered "depressive relapse" if relapsed by any of these times.

Time frame: Weeks 16, 20, 24, 30, 36

Secondary Outcomes

Treatment-Emergent Mood Symptoms

These subjects must be responders.

Time frame: Measured at Weeks 12 and 36

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.